1-15 of 15
factor viii
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Thrombosis and novel hemophilia therapies: the fine line between clotting and bleeding

Maureane Hoffman
Journal: Blood Advances
Blood Adv (2021) 5 (18): 3736.
https://doi.org/10.1182/bloodadvances.2021004802
Published: 2021
Includes: Supplemental data
Journal Articles

Population pharmacokinetics of the von Willebrand factor–factor VIII interaction in patients with von Willebrand disease

Laura H. Bukkems, Jessica M. Heijdra, Nico C. B. de Jager, Hendrika C. A. M. Hazendonk, Karin Fijnvandraat, Karina Meijer, Jeroen C. J. Eikenboom, Britta A. P. Laros-van Gorkom, Frank W. G. Leebeek, Marjon H. Cnossen, Ron A. A. Mathôt
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1513–1522.
https://doi.org/10.1182/bloodadvances.2020003891
Published: 2021
Includes: Supplemental data
Journal Articles

Molecular coevolution of coagulation factor VIII and von Willebrand factor

Philip M. Zakas, Christopher W. Coyle, Anja Brehm, Marion Bayer, Barbara Solecka-Witulska, Caelan E. Radford, Christine Brown, Kate Nesbitt, Courtney Dwyer, Christoph Kannicht, H. Trent Spencer, Eric A. Gaucher, Christopher B. Doering, David Lillicrap
Journal: Blood Advances
Blood Adv (2021) 5 (3): 812–822.
https://doi.org/10.1182/bloodadvances.2020002971
Published: 2021
Includes: Supplemental data
Journal Articles

Gut dysbiosis modulates the immune response to factor VIII in murine hemophilia A

Julie Tarrant, Matthew Cormier, Kate Nesbitt, Courtney Dwyer, Christine Hough, David Lillicrap
Journal: Blood Advances
Blood Adv (2020) 4 (12): 2644–2655.
https://doi.org/10.1182/bloodadvances.2019001144
Published: 2020
Includes: Supplemental data
Journal Articles

Laboratory monitoring of hemophilia A treatments: new challenges

Clinical Trials & Observations
Peter J. Lenting
Journal: Blood Advances
Blood Adv (2020) 4 (9): 2111–2118.
https://doi.org/10.1182/bloodadvances.2019000849
Published: 2020
Journal Articles

von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD

Clinical Trials & Observations
Ferdows Atiq, Lisette M. Schütte, Agnes E. M. Looijen, Johan Boender, Marjon H. Cnossen, Jeroen Eikenboom, Moniek P. M. de Maat, Marieke J. H. A. Kruip, Frank W. G. Leebeek
Journal: Blood Advances
Blood Adv (2019) 3 (24): 4147–4154.
https://doi.org/10.1182/bloodadvances.2019000863
Published: 2019
Journal Articles

New therapies for von Willebrand disease

Pier Mannuccio Mannucci
Journal: Blood Advances
Blood Adv (2019) 3 (21): 3481–3487.
https://doi.org/10.1182/bloodadvances.2019000368
Published: 2019
Journal Articles

Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue

Wojciech Jankowski, Joseph McGill, H. A. Daniel Lagassé, Stepan Surov, Gary Bembridge, Campbell Bunce, Edward Cloake, Mark H. Fogg, Katarzyna I. Jankowska, Abdul Khan, Joseph Marcotrigiano, Mikhail V. Ovanesov, Zuben E. Sauna
Journal: Blood Advances
Blood Adv (2019) 3 (17): 2668–2678.
https://doi.org/10.1182/bloodadvances.2019000338
Published: 2019
Includes: Supplemental data
Journal Articles

Infused factor VIII–expressing platelets or megakaryocytes as a novel therapeutic strategy for hemophilia A

Randolph B. Lyde, Hyun Sook Ahn, Karen K. Vo, Danuta J. Jarocha, John Tkaczynski, Elsa Treffeisen, Spencer K. Sullivan, Rodney M. Camire, Denise E. Sabatino, Deborah L. French, Mortimer Poncz
Journal: Blood Advances
Blood Adv (2019) 3 (9): 1368–1378.
https://doi.org/10.1182/bloodadvances.2017007914
Published: 2019
Includes: Supplemental data
Journal Articles

Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice

Rikke Stagaard, Carsten Dan Ley, Kasper Almholt, Lisbeth Høier Olsen, Tom Knudsen, Matthew J. Flick
Journal: Blood Advances
Blood Adv (2018) 2 (22): 3126–3136.
https://doi.org/10.1182/bloodadvances.2018024851
Published: 2018
Journal Articles

Gene therapy in hemophilia A: a cost-effectiveness analysis

Nicoletta Machin, Margaret V. Ragni, Kenneth J. Smith
Journal: Blood Advances
Blood Adv (2018) 2 (14): 1792–1798.
https://doi.org/10.1182/bloodadvances.2018021345
Published: 2018
Journal Articles

HLA-DRB1–factor VIII binding is a risk factor for inhibitor development in nonsevere hemophilia: a case-control study

Christine L. Kempton, Amanda B. Payne
Journal: Blood Advances
Blood Adv (2018) 2 (14): 1750–1755.
https://doi.org/10.1182/bloodadvances.2018019323
Published: 2018
Journal Articles

FVIII proteins with a modified immunodominant T-cell epitope exhibit reduced immunogenicity and normal FVIII activity

Ruth A. Ettinger, Joseph A. Liberman, Devi Gunasekera, Komal Puranik, Eddie A. James, Arthur R. Thompson, Kathleen P. Pratt
Journal: Blood Advances
Blood Adv (2018) 2 (4): 309–322.
https://doi.org/10.1182/bloodadvances.2017013482
Published: 2018
Includes: Supplemental data
Journal Articles

CD4 T cells specific for factor VIII are present at high frequency in healthy donors and comprise naïve and memory cells

Sylvain Meunier, Catherine Menier, Elodie Marcon, Sébastien Lacroix-Desmazes, Bernard Maillère
Journal: Blood Advances
Blood Adv (2017) 1 (21): 1842–1847.
https://doi.org/10.1182/bloodadvances.2017008706
Published: 2017
Includes: Supplemental data
Journal Articles

The impact of von Willebrand factor on factor VIII memory immune responses

Juan Chen, Jocelyn A. Schroeder, Xiaofeng Luo, Qizhen Shi
Journal: Blood Advances
Blood Adv (2017) 1 (19): 1565–1574.
https://doi.org/10.1182/bloodadvances.2017009209
Published: 2017
Includes: Supplemental data